Thermo Fisher doubles global footprint for drug development, commercial manufacturing

 

• Thermo Fisher Scientific (NYSE:TMO) further expanded its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
• Thermo Fisher sites currently being expanded are: Greenville, NC.; Swindon, U.K.; and Ferentino and Monza, Italy; adding 15 development and cGMP commercial production lines. These projects are expected to be completed over the next two years and will create ~1,000 jobs.
• Additionally, company recently announced significant projects in Asia-Pacific, including a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.
• "With these investments, we've nearly doubled our global footprint for drug development and commercial manufacturing, which allows us to support our customers with unmatched flexibility, expertise and scale at a time of unprecedented demand," commented Mike Shafer, senior vice president and president, pharma services.
• https://seekingalpha.com/news/3642916-thermo-fisher-doubles-global-footprint-for-drug-development-and-commercial-manufacturing